The Paradox of Pharmaceutical Hyperconnectivity
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. As we head into the dog days of summer I continue to reflect on the recent DIA and BIO annual meetings held in mid-June. At both events I was […]